Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908752 · ClinicalTrials.gov registry record · Phase 3
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 734
- Enrollment target
NCT00908752: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00908752 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 734 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00908752, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 734 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
Interventions
- DRUG Brivanib
- OTHER Brivanib Placebo
- PROCEDURE TACE Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734 participants |
| Start Date | 2009-07-20 |
| Est. Completion | 2018-01-26 |
| Phase | Phase 3 |
What the finished NCT00908752 record still lists
NCT00908752 is an interventional study that assigns participants to a tested intervention. The registered 734 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Brivanib is the first listed.
NCT00908752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00908752 about?
NCT00908752 is a clinical study titled "Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC". The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
What is the current status of trial NCT00908752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 734 participants. The study started on 2009-07-20. Estimated completion is 2018-01-26.
What interventions are being tested in trial NCT00908752?
The interventions under investigation include: Brivanib (DRUG), Brivanib Placebo (OTHER), TACE Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00908752?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00908752's enrollment target sits among peer trials
734 482nd of 2000 higher than 1,517 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI